S59-A framework to improve guidelines for patients with multimorbidity Cynthia Boyd, MD (Presenter) (Johns Hopkins, Towson, Maryland); Bruce Leff, MD (Johns Hopkins, Baltimore, Maryland); David Kent, MD (Tufts Medical Center, Boston, Massachusetts); Katrin Uhlig, MD (Tufts Medical Center, Boston, Massachusetts) PRIMARY TRACK: Guideline development SECONDARY TRACK: Guidelines for patients with multiple comorbidities BACKGROUND (INTRODUCTION): Current guideline development approaches do not prompt guideline developers to routinely consider to what degree patients with relevant comorbidity benefit similarly from a particular therapy, and do not provide tools for adapting recommendations to the comorbid patient or for prioritizing the most important recommendations within a single disease, let alone between diseases.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Understand how multimorbidity is relevant to guideline development and consumers. 2. Identify issues related to people with multimorbidity that should be considered in the development of a guideline. METHODS: A collaborative team with expertise along the continuum of medical research-from study and clinical trial design to systematic review to guideline development-generated a list of issues relevant for addressing multimorbidity at each step of guideline development. An external expert panel provided feedback on these issues. RESULTS: The issues relevant for addressing multimorbidity include the following examples, organized by guideline development processes: • in topic selection, including relevant comorbid conditions when defining the population of interest; • in work group processes, including guideline work group members and reviewers with expertise on the relevant comorbidity; • in choosing outcomes and ranking their importance, incorporating values and judgments of patients with relevant comorbidity; • in setting study criteria, explicitly choosing between the trade-offs of study designs with greater internal versus external validity; • in searches, finding evidence on subgroups or interactions; • in evidence appraisal, considering the time horizon relevant to persons with comorbid conditions;
• in quality appraisal, considering impact of comorbidity on quality of the evidence (in particular directness); and • in formulation of recommendations, considering how the presence of comorbidity impacts on the balance of benefits and harms and the strength of a recommendation. DISCUSSION (CONCLUSION): Future work of this grant focuses on developing a prioritized set of recommendations to prompt guideline developers to make guidelines more directly applicable to the patient with multimorbidity. TARGET AUDIENCE(S): 1. Clinical researcher 2. Evidence synthesizer, developer of systematic reviews or meta-analyses 3. Guideline developer 4. Guideline implementer 5. Developer of guideline-based products 6. Health care policy analyst/policymaker 7. Medical providers and executives 8. Consumers' and patients' representatives
